| Literature DB >> 29414258 |
Vivek Narayan1,2, Bonnie Ky3,2,4.
Abstract
There is growing awareness of the overlap between oncologic and cardiovascular (CV) diseases, including a wide range of CV effects of anticancer therapies. As novel anticancer therapeutics become available and cancer survival outcomes improve, the CV implications of cancer therapy become increasingly important. In addition to outlining the CV effects of commonly used cancer therapies and their consequences for long-term survivorship, this review highlights the recent efforts to improve the risk prediction and prevention of CV toxicity through the evaluation of sensitive measures for early toxicity detection and the implementation of cardioprotective strategies.Entities:
Keywords: biomarkers; cardio-oncology; cardiotoxicity; heart failure; risk factors; survivorship
Mesh:
Substances:
Year: 2018 PMID: 29414258 PMCID: PMC6722326 DOI: 10.1146/annurev-med-041316-090622
Source DB: PubMed Journal: Annu Rev Med ISSN: 0066-4219 Impact factor: 13.739